Valencia, Spain and New York, January 28, 2025 – Quibim, a healthtech firm centered on the usage of imaging biomarkers for precision medication, introduced at this time the shut of its $50 million Sequence A financing.
The corporate mentioned it has skilled progress within the variety of sufferers analyzed by its merchandise over the previous yr. Pushed by a number of regulatory approvals and world business partnerships, affected person evaluation surged by 168% quarter-on-quarter. The financing was led by Asabys (by means of its fund Sabadell Asabys II) and Buenavista Fairness Companions (by means of the BHG I fund, created in partnership with Columbus Enterprise Companions), and joined by UI Investissements, and GoHub Ventures as new traders. It was additionally joined by present traders, Amadeus Capital Companions, APEX Ventures, Partech, Adara Ventures, Leadwind (KFund’s early progress fund), Tony Fadell’s Construct Collective, and particular person investor Dr. Jonathan Milner, founding father of Abcam plc.
Quibim is devoted to the bold mission of unlocking an entire, non-invasive understanding of each tissue level within the human physique, at any second in time. To attain this, the corporate develops foundational AI fashions utilized to imaging that extract actionable insights from MRI, CT, and PET scans. These insights allow exact characterization of phenotypes and prediction of outcomes in areas comparable to oncology, immunology, neurology and metabolic problems.
That is the pathway towards reaching human digital twins, dynamic fashions that not solely replicate and permit well being monitoring but additionally improve affected person stratification, enhance the success charges of drug improvement packages, and allow therapy testing earlier than software. At the moment, the corporate is constructing digital twins on the organ and lesion stage, exemplified by options like QP-Mind, QP-Prostate, and QP-Liver.
Nevertheless, as the quantity of whole-body scans and associated imaging information continues to develop, within the coming years Quibim fashions will analyze all the physique. The imaginative and prescient of the corporate is to catalyze this revolutionary step in healthcare by merging imaging applied sciences, computing, and AI.
With over 170 installations worldwide, together with prestigious establishments like Mass Basic Brigham and Stanford, and regulatory clearances throughout the US, EU, UK, and different areas, Quibim’s know-how bridges the hole between analysis, scientific follow, and drug improvement. Final yr, Philips introduced a world partnership with Quibim to combine its AI fashions into MR scanners, whereas the corporate additionally secured strategic alliances with main biopharma giants comparable to Merck KGaA and Novartis.
“Quibim’s mission is to show imaging right into a catalyst for precision well being, and we’re deeply grateful to each our new and present traders for his or her help,” mentioned Dr. Ángel Alberich-Bayarri, CEO and co-founder of Quibim. “Our world enlargement into the U.S. is a important milestone as we work with pharmaceutical leaders and healthcare suppliers to unlock the facility of imaging to revolutionize diagnostics and enhance affected person outcomes.”
Quibim’s product portfolio consists of:
- QP-Prostate: the corporate’s flagship product is designed to boost prostate most cancers detection by means of an industry-leading AI-powered lesion detection*. CE, UKCA marked and 510(okay) cleared.
- QP-Mind: AI-based early-stage neurological illness quantification software program for quantification of early mind atrophy and lesions. CE, UKCA marked and 510(okay) cleared.
- QP-Liver: automated AI software for MR prognosis of diffuse liver ailments by means of correct quantification of tissue fats and iron ranges. CE and UKCA marked.
- QP-Insights: A platform to handle, retailer and analyze multi-omics information in scientific trials and real-world information research. QP-Insights is being utilized by world biopharmaceutical corporations, tutorial medical facilities and analysis consortiums, together with the European Most cancers Imaging Initiative to help Europe’s Beating Most cancers Plan. QP-Insights is the platform managing the biggest imaging datasets on this planet, accounting for greater than 100 million medical photographs.
With the sequence A financing, Quibim is establishing a powerful U.S. presence, constructing on its success in Europe, by means of strategic collaborations with hospitals and pharmaceutical corporations. By implementing its strategic plan and, by means of its suite of options already cleared by FDA, the corporate will help healthcare suppliers and scientific researchers to course of an unprecedented quantity of knowledge from medical scans. Moreover, Quibim’s AI-powered imaging options will empower pharmaceutical corporations by enhancing scientific trials and accelerating drug improvement with exact, actionable insights derived from imaging biomarkers.
“Asabys is thrilled to help Quibim in reworking the imaging diagnostics house,” mentioned Guillem Masferrer, Companion at Asabys Companions. “Their capacity to mix AI with imaging biomarker discovery addresses important unmet wants in oncology, neurology, and past. We’re assured that Quibim’s revolutionary options can have a profound influence on world healthcare.”
“Quibim’s know-how exemplifies the subsequent wave of precision medication,” mentioned José Mesa, Companion at Columbus and Buenavista’s consultant on the Board. “Their spectacular observe file with world pharmaceutical partnerships, together with partnerships with corporations comparable to Merck KGaA and Philips, exemplify Quibim’s position in reworking imaging information into invaluable predictions for scientific trials and therapy planning. We anticipate that as Quibim develops its pipeline of companion diagnostic instruments, we are going to see super momentum for its know-how and merchandise.”
“The foundational analysis executed by Quibim’s staff has not solely knowledgeable {industry} requirements, but additionally led to the corporate pioneering an strategy to combining radiomics and deep studying that’s now an ordinary of its personal.” mentioned Pierre Socha, Companion at Amadeus Capital Companions. “This platform strategy was novel on the time of our first funding and proved to be the precise technique for speedy scale-up.”
“Excited that Quibim’s AI enabled insights from MRI, CT and PET scans are coming to the US! Their FDA authorized precision evaluation is already being utilized by medical doctors to detect early indicators of ailments like most cancers and assist measure therapy response. Quibim has actually superior precision medication world wide!” mentioned Tony Fadell Construct Collective Principal and Nest Founder.
